UY34782A - Anticuerpos humanos para fel d1 y métodos para usarlos. - Google Patents
Anticuerpos humanos para fel d1 y métodos para usarlos.Info
- Publication number
- UY34782A UY34782A UY34782A UY34782A UY34782A UY 34782 A UY34782 A UY 34782A UY 34782 A UY34782 A UY 34782A UY 34782 A UY34782 A UY 34782A UY 34782 A UY34782 A UY 34782A
- Authority
- UY
- Uruguay
- Prior art keywords
- fel
- methods
- human antibodies
- antibodies
- human
- Prior art date
Links
- 241000950314 Figura Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16311—Influenzavirus C, i.e. influenza C virus
- C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención proporciona anticuerpos que se unen al alérgeno de gato, Fel d1, composicione s que comprenden los anticuerpos, ácidos nucleicos que codifican los anticuerpos y métodos de uso d e los anticuerpos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261642083P | 2012-05-03 | 2012-05-03 | |
| US201261718044P | 2012-10-24 | 2012-10-24 | |
| US201361783312P | 2013-03-14 | 2013-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY34782A true UY34782A (es) | 2013-11-29 |
Family
ID=48326501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY34782A UY34782A (es) | 2012-05-03 | 2013-05-03 | Anticuerpos humanos para fel d1 y métodos para usarlos. |
Country Status (32)
| Country | Link |
|---|---|
| US (6) | US9079948B2 (es) |
| EP (3) | EP3660047B1 (es) |
| JP (2) | JP6400569B2 (es) |
| KR (1) | KR102185516B1 (es) |
| CN (2) | CN104411719B (es) |
| AR (1) | AR090914A1 (es) |
| AU (2) | AU2013256251C1 (es) |
| BR (2) | BR122019023685B1 (es) |
| CA (1) | CA2871077C (es) |
| CY (2) | CY1124023T1 (es) |
| DK (1) | DK2844672T3 (es) |
| ES (2) | ES2780392T3 (es) |
| HK (1) | HK1202123A1 (es) |
| HR (2) | HRP20211932T1 (es) |
| HU (2) | HUE057062T2 (es) |
| IL (1) | IL235121B (es) |
| IN (1) | IN2014DN08767A (es) |
| JO (1) | JO3820B1 (es) |
| LT (2) | LT2844672T (es) |
| MX (2) | MX2014013371A (es) |
| MY (3) | MY164101A (es) |
| NZ (2) | NZ733480A (es) |
| PL (2) | PL2844672T3 (es) |
| PT (2) | PT2844672T (es) |
| RS (2) | RS62636B1 (es) |
| RU (1) | RU2658491C2 (es) |
| SG (3) | SG10202102919XA (es) |
| SI (2) | SI2844672T1 (es) |
| TW (2) | TW201803901A (es) |
| UY (1) | UY34782A (es) |
| WO (1) | WO2013166236A1 (es) |
| ZA (3) | ZA201407302B (es) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090137416A1 (en) | 2001-01-16 | 2009-05-28 | Regeneron Pharmaceuticals, Inc. | Isolating Cells Expressing Secreted Proteins |
| DK2564695T3 (en) | 2009-07-08 | 2015-05-26 | Kymab Ltd | Animal models and therapeutic molecules |
| EP2758535B1 (en) | 2011-09-19 | 2016-11-09 | Kymab Limited | Antibodies, variable domains&chains tailored for human use |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| EP3036543B1 (en) | 2013-08-23 | 2019-06-19 | Regeneron Pharmaceuticals, Inc. | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit) |
| CN105683365A (zh) | 2013-10-01 | 2016-06-15 | 科马布有限公司 | 动物模型及治疗分子 |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| SI3221359T1 (sl) | 2014-11-17 | 2020-08-31 | Regeneron Pharmaceuticals, Inc. | Metode zravljenja tumorja z uporabo bispecifičnega protitelesa CD3XCD20 |
| PL3277725T3 (pl) | 2015-03-30 | 2021-06-14 | Regeneron Pharmaceuticals, Inc. | Regiony stałe łańcucha ciężkiego o zmniejszonym wiązaniu do receptorów Fc gamma |
| TW202330904A (zh) | 2015-08-04 | 2023-08-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| US10835600B2 (en) * | 2015-09-08 | 2020-11-17 | Universität Zürich | Compositions against cat allergy |
| MA44723A (fr) | 2016-04-18 | 2019-02-27 | Celldex Therapeutics Inc | Anticorps agonistes se liant au cd40 humain et leurs utilisations |
| EP3504328A1 (en) | 2016-08-24 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| WO2018118713A1 (en) * | 2016-12-22 | 2018-06-28 | Regeneron Pharmaceuticals, Inc. | Method of treating an allergy with allergen-specific monoclonal antibodies |
| JP7112409B2 (ja) * | 2017-01-24 | 2022-08-03 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 抗Ｆｅｌ Ｄ１抗体を含む組成物及びヒトのネコアレルギーの少なくとも１つの症状を減少させる方法 |
| KR20210084695A (ko) | 2017-07-06 | 2021-07-07 | 리제너론 파마슈티칼스 인코포레이티드 | 당단백질을 만들기 위한 세포 배양 과정 |
| SG11202004380QA (en) | 2017-12-22 | 2020-06-29 | Regeneron Pharma | System and method for characterizing drug product impurities |
| KR20200115485A (ko) | 2018-01-31 | 2020-10-07 | 리제너론 파마슈티칼스 인코포레이티드 | 약물 생성물 불순물을 특성화하기 위한 시스템 및 방법 |
| TWI786265B (zh) | 2018-02-02 | 2022-12-11 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| KR20200127979A (ko) | 2018-02-28 | 2020-11-11 | 리제너론 파마슈티칼스 인코포레이티드 | 바이러스 오염물질을 확인하기 위한 시스템 및 방법 |
| DK3768709T3 (da) | 2018-03-19 | 2024-01-29 | Regeneron Pharma | Mikrochip-kapillærelektroforese-assays og reagenser |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| AU2019270181B2 (en) * | 2018-05-18 | 2023-06-01 | Cz Biohub Sf, Llc | Methods of isolating allergen-specific antibodies from humans and uses thereof |
| KR20210052389A (ko) | 2018-08-27 | 2021-05-10 | 리제너론 파마슈티칼스 인코포레이티드 | 다운스트림 정제에서의 라만 분광법의 사용 |
| AU2019333047A1 (en) | 2018-08-30 | 2020-12-03 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
| FI3857237T3 (fi) | 2019-01-16 | 2023-05-03 | Regeneron Pharma | Disulfidisidosten luonnehtimismenetelmiä |
| SG11202110911RA (en) | 2019-05-13 | 2021-10-28 | Regeneron Pharma | Improved competitive ligand binding assays |
| EP4034870A1 (en) | 2019-09-24 | 2022-08-03 | Regeneron Pharmaceuticals, Inc. | Systems and methods for chromatography use and regeneration |
| BR112022009974A2 (pt) | 2019-11-25 | 2022-08-16 | Regeneron Pharma | Métodos de produção de um polímero ou micropartículas revestidas com polímero, para produzir microesferas poliméricas ou revestidas com polímero e para produzir micropartículas, composição de liberação sustentada, micropartículas, e, composição farmacêutica |
| US11835527B2 (en) | 2020-01-21 | 2023-12-05 | Regeneron Pharmaceuticals, Inc. | Deglycosylation methods for electrophoresis of glycosylated proteins |
| US20220064270A1 (en) | 2020-08-26 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Method of treating an allergy with allergen-specific monoclonal antibodies |
| CA3192999A1 (en) | 2020-08-31 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants |
| WO2022115588A1 (en) | 2020-11-25 | 2022-06-02 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
| KR20230121854A (ko) | 2020-12-17 | 2023-08-21 | 리제너론 파아마슈티컬스, 인크. | 단백질-캡슐화 마이크로겔의 제작 |
| WO2022159432A1 (en) | 2021-01-20 | 2022-07-28 | Regeneron Pharmaceuticals, Inc. | Methods of improving protein titer in cell culture |
| EP4302098A1 (en) | 2021-03-03 | 2024-01-10 | Regeneron Pharmaceuticals, Inc. | Systems and methods for quantifying and modifying protein viscosity |
| EP4315344A1 (en) | 2021-03-26 | 2024-02-07 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing mixing protocols |
| WO2022256383A1 (en) | 2021-06-01 | 2022-12-08 | Regeneron Pharmaceuticals, Inc. | Micropchip capillary electrophoresis assays and reagents |
| TW202326138A (zh) | 2021-09-08 | 2023-07-01 | 美商再生元醫藥公司 | 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法 |
| JP2024531800A (ja) | 2021-09-20 | 2024-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗体の不均一性を制御する方法 |
| TW202331252A (zh) | 2021-10-07 | 2023-08-01 | 美商再生元醫藥公司 | Ｐｈ計校準與校正 |
| JP2024538673A (ja) | 2021-10-07 | 2024-10-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ｐＨモデリング及び制御のシステム及び方法 |
| WO2023076340A1 (en) | 2021-10-26 | 2023-05-04 | Regeneron Pharmaceuticals, Inc. | Systems and methods for generating laboratory water and distributing laboratory water at different temperatures |
| CN114113278B (zh) * | 2021-11-24 | 2024-08-02 | 中国计量科学研究院 | 一种基于质谱的体外诊断试剂抗体的表位定位方法 |
| WO2023177836A1 (en) | 2022-03-18 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Methods and systems for analyzing polypeptide variants |
| WO2023250419A1 (en) | 2022-06-23 | 2023-12-28 | Regeneron Pharmaceuticals, Inc. | Methods of identifying and evaluating cat allergy gene signatures in a subject by determining a stratified score based on gene expression |
| WO2024130048A1 (en) | 2022-12-16 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| US20240245779A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Methods of modeling liquid protein composition stability |
| WO2024158961A1 (en) | 2023-01-25 | 2024-08-02 | Regeneron Pharmaceuticals, Inc. | Mass spectrometry-based characterization of antibodies co-expressed in vivo |
| WO2024163708A1 (en) | 2023-02-01 | 2024-08-08 | Regeneron Pharmaceuticals, Inc. | Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis |
| US20240280551A1 (en) | 2023-02-22 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | System suitability parameters and column aging |
| US20240352103A1 (en) | 2023-03-01 | 2024-10-24 | Regeneron Pharmaceuticals, Inc. | Anti-fel d1 antibody formulations |
| WO2024200854A1 (en) | 2023-03-31 | 2024-10-03 | Alk-Abelló A/S | Allergen binding antibodies suitable for treating tree pollen allergies |
| CN117004650B (zh) * | 2023-06-25 | 2024-05-14 | 山东立菲生物产业有限公司 | 一种猫皮屑过敏原组分feld1双链二聚体重组蛋白、制备方法及应用 |
| CN117069865B (zh) * | 2023-10-12 | 2024-03-01 | 中国农业科学院饲料研究所 | 一种基于T细胞抗原表位猫过敏原蛋白嵌合肽cFel d 1的原核表达及其卵黄抗体的制备 |
| CN117964767B (zh) * | 2024-03-29 | 2024-08-06 | 北京恩泽康泰生物科技有限公司 | 抗rage抗体、细胞外囊泡及其制备方法和应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07503239A (ja) * | 1992-01-21 | 1995-04-06 | イミユロジク・フアーマシユーチカル・コーポレーシヨン | ヒスタミン誘導体を免疫調節剤として免疫療法で用いる方法 |
| AU5958494A (en) | 1992-12-21 | 1994-07-19 | Tanox Biosystems, Inc. | Allergen-specific iga monoclonal antibodies and related products for allergy treatment |
| GB0002386D0 (en) | 2000-02-02 | 2000-03-22 | Novartis Nutrition Ag | Therapeutic composition |
| US6849259B2 (en) | 2000-06-16 | 2005-02-01 | Symphogen A/S | Polyclonal antibody composition for treating allergy |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| CN103203016A (zh) * | 2005-03-18 | 2013-07-17 | 赛托斯生物技术公司 | 猫变应原融合蛋白及其用途 |
| US7566456B2 (en) * | 2005-06-23 | 2009-07-28 | Haiming Chen | Allergen vaccine proteins for the treatment and prevention of allergic diseases |
| GB0513878D0 (en) * | 2005-07-06 | 2005-08-10 | Mars Inc | Cat allergen |
| WO2007065633A1 (en) * | 2005-12-05 | 2007-06-14 | Imvision Ag | Modulation of the immune response by administration of intralymphatic transduction allergen (itag) -molecules |
| WO2007113633A2 (en) * | 2006-04-03 | 2007-10-11 | Pfizer Products Inc. | Immunogenic compositions comprising cat allergen fel dl |
| BRPI0712224B8 (pt) | 2006-06-02 | 2021-05-25 | Regeneron Pharma | anticorpos de alta afinidade para o receptor de il-6 humano e composições farmacêuticas |
| AT503690A1 (de) | 2006-06-09 | 2007-12-15 | Biomay Ag | Hypoallergene moleküle |
| EP1921142A1 (en) * | 2006-11-07 | 2008-05-14 | Cytos Biotechnology AG | Selection of human monoclonal antibodies by eukaryotic cell display |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| NZ614857A (en) * | 2007-03-29 | 2015-04-24 | Genmab As | Bispecific antibodies and methods for production thereof |
| CA2688275A1 (en) * | 2007-05-31 | 2008-12-04 | Genmab A/S | Stable igg4 antibodies |
| GB0710529D0 (en) | 2007-06-01 | 2007-07-11 | Circassia Ltd | Vaccine |
| US8454953B2 (en) * | 2007-07-09 | 2013-06-04 | Nestec Sa | Methods for reducing allergies caused by environmental allergens |
| WO2009023540A1 (en) | 2007-08-10 | 2009-02-19 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human nerve growth factor |
| JO3340B1 (ar) * | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
-
2013
- 2013-05-01 JO JOP/2013/0131A patent/JO3820B1/ar active
- 2013-05-02 AU AU2013256251A patent/AU2013256251C1/en active Active
- 2013-05-02 KR KR1020147033137A patent/KR102185516B1/ko active IP Right Grant
- 2013-05-02 ES ES13721544T patent/ES2780392T3/es active Active
- 2013-05-02 DK DK13721544.8T patent/DK2844672T3/da active
- 2013-05-02 MY MYPI2014002857A patent/MY164101A/en unknown
- 2013-05-02 PT PT137215448T patent/PT2844672T/pt unknown
- 2013-05-02 CN CN201380035000.9A patent/CN104411719B/zh active Active
- 2013-05-02 HU HUE19218187A patent/HUE057062T2/hu unknown
- 2013-05-02 MY MYPI2020006733A patent/MY195564A/en unknown
- 2013-05-02 LT LTEP13721544.8T patent/LT2844672T/lt unknown
- 2013-05-02 PL PL13721544T patent/PL2844672T3/pl unknown
- 2013-05-02 ES ES19218187T patent/ES2898372T3/es active Active
- 2013-05-02 CA CA2871077A patent/CA2871077C/en active Active
- 2013-05-02 NZ NZ733480A patent/NZ733480A/en unknown
- 2013-05-02 EP EP19218187.3A patent/EP3660047B1/en active Active
- 2013-05-02 MY MYPI2017701565A patent/MY181422A/en unknown
- 2013-05-02 PL PL19218187T patent/PL3660047T3/pl unknown
- 2013-05-02 TW TW106119738A patent/TW201803901A/zh unknown
- 2013-05-02 SG SG10202102919XA patent/SG10202102919XA/en unknown
- 2013-05-02 SG SG10201608378UA patent/SG10201608378UA/en unknown
- 2013-05-02 MX MX2014013371A patent/MX2014013371A/es active IP Right Grant
- 2013-05-02 BR BR122019023685-2A patent/BR122019023685B1/pt active IP Right Grant
- 2013-05-02 RS RS20211475A patent/RS62636B1/sr unknown
- 2013-05-02 SG SG11201406748QA patent/SG11201406748QA/en unknown
- 2013-05-02 PT PT192181873T patent/PT3660047T/pt unknown
- 2013-05-02 JP JP2015510445A patent/JP6400569B2/ja active Active
- 2013-05-02 BR BR112014026852-5A patent/BR112014026852B1/pt active IP Right Grant
- 2013-05-02 IN IN8767DEN2014 patent/IN2014DN08767A/en unknown
- 2013-05-02 EP EP21194412.9A patent/EP3978522A3/en active Pending
- 2013-05-02 RS RS20200539A patent/RS60282B1/sr unknown
- 2013-05-02 EP EP13721544.8A patent/EP2844672B1/en active Active
- 2013-05-02 AR ARP130101494 patent/AR090914A1/es unknown
- 2013-05-02 HR HRP20211932TT patent/HRP20211932T1/hr unknown
- 2013-05-02 CN CN201910294004.8A patent/CN110240651B/zh active Active
- 2013-05-02 LT LTEP19218187.3T patent/LT3660047T/lt unknown
- 2013-05-02 US US13/875,401 patent/US9079948B2/en active Active
- 2013-05-02 HU HUE13721544A patent/HUE049440T2/hu unknown
- 2013-05-02 TW TW102115645A patent/TWI644921B/zh active
- 2013-05-02 SI SI201331698T patent/SI2844672T1/sl unknown
- 2013-05-02 NZ NZ701124A patent/NZ701124A/en unknown
- 2013-05-02 RU RU2014148502A patent/RU2658491C2/ru active
- 2013-05-02 WO PCT/US2013/039192 patent/WO2013166236A1/en active Application Filing
- 2013-05-02 SI SI201331935T patent/SI3660047T1/sl unknown
- 2013-05-03 UY UY34782A patent/UY34782A/es active IP Right Grant
-
2014
- 2014-10-08 ZA ZA2014/07302A patent/ZA201407302B/en unknown
- 2014-10-19 IL IL235121A patent/IL235121B/en active IP Right Grant
- 2014-11-03 MX MX2020003864A patent/MX2020003864A/es unknown
-
2015
- 2015-03-13 HK HK15102575.2A patent/HK1202123A1/xx unknown
- 2015-06-05 US US14/732,578 patent/US9475869B2/en active Active
-
2016
- 2016-09-13 US US15/263,848 patent/US10047152B2/en active Active
-
2017
- 2017-01-26 US US15/416,176 patent/US10047153B2/en active Active
- 2017-06-14 JP JP2017116808A patent/JP6603269B2/ja active Active
-
2018
- 2018-05-03 AU AU2018203087A patent/AU2018203087B9/en active Active
- 2018-07-05 US US16/028,275 patent/US11174305B2/en active Active
-
2020
- 2020-04-23 HR HRP20200652TT patent/HRP20200652T1/hr unknown
- 2020-05-04 CY CY20201100408T patent/CY1124023T1/el unknown
- 2020-08-25 ZA ZA2020/05273A patent/ZA202005273B/en unknown
-
2021
- 2021-10-13 US US17/500,418 patent/US20220025029A1/en active Pending
- 2021-12-20 CY CY20211101115T patent/CY1124819T1/el unknown
-
2022
- 2022-03-09 ZA ZA2022/02846A patent/ZA202202846B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY34782A (es) | Anticuerpos humanos para fel d1 y métodos para usarlos. | |
| UY34680A (es) | Anticuerpos humanos anti-cd27, métodos, y usos | |
| TWD165141S (zh) | 手鐲 | |
| UY34721A (es) | Anticuerpos anti-hla-b*27 y usos de éstos. | |
| EA201590993A1 (ru) | Гетеродимерные иммуноглобулины | |
| CL2015002562A1 (es) | Anticuerpos e inmunoconjugados anti-b7-h4 | |
| UY34876A (es) | Anticuerpos anti-egfr y usos de los mismos | |
| UY34822A (es) | Composiciones y métodos para silenciar la expresión genética | |
| TWD165363S (zh) | 錶殼 | |
| UY34885A (es) | Proteínas de unión anti-mesotelina | |
| TWD162033S (zh) | 手錶 | |
| CO7020877A2 (es) | Anticuerpos anti-asic1 y usos de los mismos | |
| UY34124A (es) | Cerramiento y método para conformarlo | |
| TWD174677S (zh) | 手錶 | |
| BR112015023440A2 (pt) | torradeira para tortilha aperfeiçoada | |
| BR112014027219A2 (pt) | método | |
| UY34829A (es) | Nueva dosificación y formulación | |
| TWD160996S (zh) | 分線器 | |
| TWD172356S (zh) | 錶殼 | |
| TWD156117S (zh) | 髮夾 | |
| TWD155524S (zh) | 髮夾 | |
| TWD155523S (zh) | 髮夾 | |
| TWD167061S (zh) | 機車 | |
| TWD154454S (zh) | 動物玩具 | |
| TWD154455S (zh) | 動物玩具 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 110 | Patent granted |
Effective date: 20220303 |